This FDA-approved wearable tracks heart health, giving cardiac patients peace of mind
Kfar Saba-based wearables startup HealthWatch announced on Tuesday the start of their new joint venture with Chinese pharmaceutical firm Yiling, giving them entry into the highly prized Sino market and a US$20 million strategic investment to help ease the process.
According to the company, US$5 million of the financing will be used for applying for their exclusive license for marketing in China as a new company, while the other US$15 million will be put into product improvements, enlarging clinical studies, as well as launching marketing and sales efforts in various geographies.
Up to this point, HealthWatch had received US$10 million in funding from private investors, angel groups, and a Chinese VC. This new round brings them to US$30 million in total funding.
Co-founded in 2010 by Chairman Dr. Yoram Romem and Director and CFO Amos Shattner, HealthWatch has developed a heart monitoring device that is capable of providing continuous updates on the health of the user.
Interestingly, both co-founders were part of the successful parking app Pango before moving into this sector.
The idea for the product came after Romem’s father suffered a heart attack. An otherwise healthy man, the incident came as a bit of a shock. A former navigator in the Israeli Air Force, he thought of the Master Caution light in a fighter jet that tells the pilot that there is an issue that demands immediate attention, which lead Romem to think about the need for early warning systems for the body.
What emerged from this was a wearable product comprised of sensors that are embedded into an undershirt that can be worn under the user’s regular clothes and transmit data about the wearer back to medical professionals through the cloud.
Comprising four elements, the hWear Digital Garment (the shirt), the MasterCaution Device which sits in a small pocket on the shirt, the MasterCaution app, and the MasterCaution Cloud, the company says that their product serves as a replacement for standard ECG tests. They have already received approval from the FDA as well as their CE mark for the European market.
The shirt, with options for men and women, is described to be similar to a compression top like the kind that is used for working out, is able to constantly collect the user’s vitals, all without the need to attach electrodes to the wearer’s skin.
“Figuring out how to connect to the wearer comfortably and without wires was one of the major challenges in developing the product,” HealthWatch’s International Sales Manager Limor Nuri told Geektime.
She explains that a primary goal of the product is to allow their users, people who have recently had a heart-related incident or others who are at high risk, to live normally without always worrying about if they are about to have a heart attack. This means fewer trips to the hospital for routine checkups that can now be done remotely.
Moving forward with their new funding in hand, Nuri says that they hope to continue making adaptations to the product according to market feedback. Viewing the shirt as a platform that can provide a range of data points, Nuri told Geektime that, “Today if you look at the data that you can take from the shirt, temperature, heart rate, location, this is just the start.”
They want to add SpO2 sensors that measure the amount of oxygen in the blood, as well as a mechanism for checking blood pressure, essentially becoming a mobile nurse station. Additionally, they also want to make more apps for elements like fitness, pregnancy, and possibly for people in special jobs like pilots on jetliners.
A growing global focus on wearable health solutions
As Geektime has noted in recent articles, there continues to be a strong interest from Chinese companies in Israeli tech know-how, and a willingness to form partnerships like these joint ventures. In particular, as China (and the rest of the world for that matter) gears up to deal with an aging population, they are searching for healthcare solutions that can cut costs and keep the system from buckling under the weight of a large generation of older adults.
The recent trend in healthcare has pointed towards prevention and early detection, and remote solutions that keep the patient out of the hospital as much as possible. This is an important point for countries like China where the hospital is the primary point of care, lacking many of the private clinics and home options available in the West. Add to this shortage of care the spike in heart issues related to changes and diet (and likely environmental as well), and the need for solutions only becomes more explicit.
Nuri says that the process of getting permissions in China will likely take somewhere between a year and a half to two years, meaning that it will take some time for the fruits of their efforts to ripen. However, given the size of the market and for disrupting the current system there, Romem and his team are confident that it is worth the effort.
In exploring the partnership, Romem said that they first found their way into the Chinese marketplace through interactions with local investors who had participated in their earlier round. By expanding this relationship, they were able to link up with Yiling, an established public pharmaceutical company that specialised in cardiac medicine and owns a large hospital. It would seem that by laying the groundwork through local members of the scene, HealthWatch was able to become visible when Yiling went looking for a device partner.
Also Read: FitMeIn fits in undisclosed pre-Series A from Japanese healthtech firm FiNC
Romem admits that finding the right partner in China can be difficult, especially coming as an outsider. “Being strangers in China, we had natural concerns of communication and understanding who is a serious player, fitting to the type of product we offer,” he said.
He told entrepreneurs who are looking at moving into China that they should study the market needs and trends. “Not every product fits the Chinese market, even if it succeeds in the west. Find a local partner, preferably a Chinese investor, preferably with good English and experience in working with the western companies, who will help you in finding the strategic partner.”
Beyond the technical challenges, there are always cultural barriers. He says that doing business there requires a lot of patience and openness to the Chinese way of thinking, and advises “listening before telling them what to do.” This can contrast with the Israeli mode of operation, which can be tough but necessary.
Nuri makes the point that their product is actually defined as a medical device, as opposed to the various consumer wearables out there that check heartbeats and count steps.
While I have recently become a fan of the gamified health tracker, I am a little less confident in its accuracy. This fudging of the stats can be fine for me, a relatively healthy and active person who is mostly interested, but would be far less so for someone who has recently experienced a cardiac incident and needs to have the correct numbers being reported.
Devices like the MasterCaution have the potential to dramatically alter the quality of life for heart disease patients for the better. By keeping them out of the hospital, which itself can put them at risk, costs and stress levels can be kept to a minimum. More importantly, by making the process of performing these checks less of a hassle, people are more likely to actually make use of them, and the constant stream of data is always better than the intermittent tests at the hospital.
The article Israeli HealthWatch – inspired by founder’s father’s heart attack – receives $20M to enter China first appeared on Geektime.
The post Israeli HealthWatch – inspired by founder’s father’s heart attack – receives US$20M to enter China appeared first on e27.
from e27 http://ift.tt/2jcgEhM